as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹711.8
Change
-27.2 (-3.68%)
Open
₹740.0
Prev. Close
₹739.0
Day High
₹740.1
Day Low
₹706.25
Volume Analysis
Traded
27,961
Delivered
24,524
Delivery %
21.35%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (4)
- •High debt-to-equity ratio (1.15)
- •Low return on equity (-25.2%)
- •Below-average fundamentals quality score (29/100)
- •Low operating margin (1.3%)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹766.36 | ₹753.23 | ₹732.51 | ₹719.38 | ₹698.66 | ₹685.53 | ₹664.81 |
| Fibonacci | ₹753.23 | ₹740.3 | ₹732.31 | ₹719.38 | ₹706.45 | ₹698.46 | ₹685.53 |
| Camarilla | ₹721.11 | ₹718.01 | ₹714.9 | ₹719.38 | ₹708.7 | ₹705.59 | ₹702.49 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+0.37%
1 Week
-1.06%
1 Month
+22.42%
3 Months
+0.08%
6 Months
+27.6%
1 Year
-13.11%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-17.64%
Net margin -15.19% × asset turnover 0.48x × equity multiplier 2.42x
Company Overview
Sector
Chemicals
Market Cap
₹1,674 Cr
ROE
-25.2%
Book Value
₹175.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Astec Lifesciences Ltd scores weakly on TopFund's composite fundamentals check within the Chemicals sector, at 29/100. The strongest factor is Corporate Governance (66/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising; high debt-to-equity ratio (1.15); low return on equity (-25.2%). FII holding has been falling.
TopFund Score — Fundamentals Quality
29/100 — WeakData confidence: 74/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −Stock is trading at 4.28 times its book value
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -4.18% over past five years.
- −Company has a low return on equity of -26.0% over last 3 years.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Astec Lifesciences replies to BSE volume inquiry, saying no undisclosed developments exist.
Exchange has sought clarification from Astec Lifesciences Ltd on September 18, 2026, with reference to Movement in Volume.
Astec Lifesciences confirms no undisclosed developments behind recent volume increase.
Exchange has sought clarification from Astec Lifesciences Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors …
Astec Lifesciences says no undisclosed developments explain recent share volume rise.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 143 | 111 | 51 | 154 | 69 | 99 | 94 | 120 | 91 | 74 | 125 | 159 | 84 |
| Expenses + | 140 | 114 | 69 | 141 | 116 | 118 | 100 | 114 | 102 | 80 | 121 | 149 | 84 |
| Operating Profit | 3 | -3 | -18 | 13 | -46 | -20 | -6 | 6 | -11 | -7 | 4 | 9 | -1 |
| OPM % | 2.2% | -3.1% | -36.0% | 8.0% | -67.0% | -20.0% | -6.0% | 4.6% | -12.0% | -9.0% | 3.2% | 6.0% | -0.8% |
| Other Income + | 2 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | -1 | 3 | 1 |
| Interest | 6 | 6 | 6 | 7 | 7 | 9 | 10 | 10 | 11 | 8 | 7 | 8 | 8 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 11 | 11 | 12 | 11 | 10 | 11 | 12 | 11 |
| Profit before tax | -11 | -18 | -32 | -1 | -62 | -39 | -25 | -16 | -33 | -24 | -16 | -8 | -19 |
| Tax % | -26.0% | -24.0% | -24.0% | 4.0% | -36.0% | 0.0% | 61.0% | 3.0% | 0.0% | 0.0% | 0.0% | -2.0% | 0.0% |
| Net Profit + | -8 | -13 | -24 | -1 | -40 | -39 | -40 | -16 | -33 | -24 | -16 | -8 | -19 |
| EPS in Rs | -4 | -6 | -11 | 0 | -18 | -17 | -18 | -7 | -15 | -11 | -7 | -3 | -8 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 267 | 233 | 299 | 368 | 431 | 523 | 555 | 677 | 628 | 458 | 381 | 448 | 441 |
| Expenses + | 213 | 201 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 448 | 453 | 435 |
| Operating Profit | 54 | 32 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -4 | 6 |
| OPM % | 20.0% | 14.0% | 21.0% | 19.0% | 18.0% | 16.0% | 20.0% | 23.0% | 12.0% | -1.3% | -17.0% | -1.0% | 1.3% |
| Other Income + | -16 | 4 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 6 | 6 | 3 | 3 |
| Interest | 13 | 13 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 35 | 31 |
| Depreciation | 13 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 | 44 |
| Profit before tax | 13 | 12 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -81 | -67 |
| Tax % | -17.0% | 59.0% | 33.0% | 37.0% | 36.0% | 23.0% | 27.0% | 26.0% | 27.0% | -24.0% | -4.0% | 0.0% | — |
| Net Profit + | 15 | 5 | 19 | 35 | 36 | 48 | 65 | 90 | 26 | -47 | -135 | -81 | -67 |
| EPS in Rs | 7 | 2 | 9 | 16 | 16 | 21 | 29 | 40 | 11 | -21 | -60 | -36 | -30 |
| Dividend Payout % | 16.0% | 0.0% | 15.0% | 8.0% | 8.0% | 6.0% | 5.0% | 3.0% | 12.0% | 0.0% | 0.0% | 0.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 116 | 99 | 119 | 150 | 183 | 227 | 290 | 377 | 400 | 350 | 215 | 368 |
| Borrowings + | 93 | 127 | 127 | 125 | 176 | 99 | 187 | 279 | 341 | 494 | 555 | 449 |
| Other Liabilities + | 133 | 85 | 69 | 119 | 83 | 226 | 181 | 221 | 219 | 112 | 92 | 102 |
| Total Liabilities | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
| Fixed Assets + | 133 | 95 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 459 |
| CWIP | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 20 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 216 | 215 | 223 | 256 | 275 | 354 | 349 | 534 | 534 | 424 | 361 | 463 |
| Total Assets | 362 | 330 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 975 | 881 | 942 |
| Equity Capital | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 7 | -13 | 19 | 65 | 15 | 168 | -8 | 24 | 75 | 10 | -8 | -81 |
| Cash from Investing Activity + | -19 | -17 | -18 | -49 | -52 | -74 | -73 | -104 | -113 | -135 | -15 | -4 |
| Cash from Financing Activity + | 12 | 31 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 | 94 |
| Net Cash Flow | 0 | 2 | 1 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 |
| CFO/OP | 19 | -24 | 41 | 116 | 41 | 219 | 13 | 34 | 104 | -211 | 20 | 1,796 |
| Free Cash Flow | -13 | -39 | -1 | 15 | -37 | 123 | -111 | -80 | -42 | -125 | -24 | -86 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 21.74% | 22.22% | 24.12% | 28.85% | 28.2% | 26.64% | 24.53% | 24.84% | 23.57% | 24.82% | 24.67% | 24.69% |
| Promoters | 66.75% | 66.75% | 66.75% | 66.75% | 66.74% | 66.74% | 70.87% | 70.87% | 72.42% | 71.97% | 71.97% | 71.97% |
| FII | 1.33% | 1.28% | 1.25% | 1.03% | 0.53% | 1.2% | 0.25% | 0.02% | 0.0% | 0.04% | 0.03% | 0.01% |
| DII | 10.16% | 9.74% | 7.88% | 3.37% | 4.5% | 5.4% | 4.34% | 4.26% | 4.01% | 3.17% | 3.33% | 3.33% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Chemicals — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Astec Lifesciences Ltd (this stock) | 1,674 | — | 4.29 | -25.2% |
| Bhageria Industries Ltd | 1,684 | 24.4 | 2.81 | 7.03% |
| Indokem Ltd. | 1,699 | 759.0 | 26.62 | 1.69% |
| Shre Push Chem & Fert Ltd | 1,636 | 22.7 | 2.68 | 12.1% |
| Vidhi Spclty F Ingrdnts L | 1,727 | 32.4 | 5.27 | 15.6% |
| Bharat Rasayan Ltd | 1,741 | 11.9 | 1.36 | 12.2% |
| Insecticides (i) Ltd | 1,758 | 14.0 | 1.44 | 12.0% |
Which Mutual Funds Hold Astec Lifesciences Ltd?
Frequently Asked Questions about Astec Lifesciences Ltd
Astec Lifesciences Ltd (ASTEC) closed at ₹711.8 on NSE on 28 September 2026, down 27.2 (3.68%) from the previous close.
Astec Lifesciences Ltd trades on the NSE (National Stock Exchange of India) under the symbol ASTEC.
Astec Lifesciences Ltd has a dividend yield of 0.0%.
Astec Lifesciences Ltd's 52-week high is ₹942.0 and its 52-week low is ₹512.0.
Astec Lifesciences Ltd has a market capitalisation of ₹1,674 crore.
Astec Lifesciences Ltd has a TopFund Quality Score of 29/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Astec Lifesciences Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.